23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07 2022 - 8:00AM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company with a mission to help
people access, understand, and benefit from the human genome, is
presenting a trials-in-progress poster detailing tumor types being
evaluated in the expansion phase of its ongoing Phase 1 study for
23ME-00610, an investigational antibody targeting CD200R1 in
patients with advanced solid malignancies, at the Society for
Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November
8-12, 2022 in Boston, Massachusetts.
The poster includes details on how the monotherapy activity of
23ME-00610 will be evaluated in tumor indication-specific expansion
cohorts (N~15/cohort), which include clear cell renal cell
carcinoma; epithelial ovarian, fallopian tube or primary peritoneal
carcinoma; neuroendocrine cancers including small cell lung cancer;
and microsatellite instability-high (MSI-H) or tumor mutational
burden-high (TMB-H) cancers that have progressed on standard
therapies. A cohort of adolescents with locally advanced
unresectable, or metastatic solid malignancies will also be
enrolled.
The tumor indications for the expansion phase were selected
based on pre-clinical and published data of the activity and
expression of CD200R1 and its ligand, CD200, together with immune
cell and tumor characteristics that have the potential to increase
the likelihood of a response to CD200R1 inhibition.
23andMe has more than 13 million genotyped customers, over 80%
of whom consent to participate in research. 23andMe scientists
study the aggregate, de-identified genetics of these participants,
alongside more than 4 billion self-reported health data points.
Using these data and sophisticated bioinformatic analyses, 23andMe
has discovered an immuno-oncology genetic signature to pinpoint
areas of the genome that may harbor promising targets for cancer
immunotherapies. One of these targets, CD200R1, is a receptor found
predominantly on immune cells; by targeting this receptor,
23ME-00610 blocks CD200 on tumor cells from binding to CD200R1 on
T-cells and myeloid cells, which may restore their ability to kill
cancer cells.
“Our hypothesis, backed by published research, is that drug
targets based on human genetics are more likely to prove successful
than those with no underlying human genetic evidence,'' said
Jennifer Low, MD, PhD, Head of Therapeutics Development at 23andMe.
“We are testing if our antibody has activity in a variety of tumor
types including those that traditionally don't respond to
anti-PD(L)-1 treatment. We hope that 23ME-00610 will ultimately
provide clinical benefit to patients with cancer.”
Poster Details
Title: A Phase 1 Dose Escalation and Expansion
Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with
Advanced Solid Malignancies.Session: Annual
Meeting Regular Poster Abstract PresenterAbstract/Poster
Number: 758Location: Hall C Date
and Time: Friday, November 11, 2022 - 9:00 a.m. – 8:30
p.m. ET
About 23ME-0061023ME-00610 is a high-affinity
humanized monoclonal antibody that is designed to bind to the
CD200R1 receptor and prevent the interaction of CD200 and CD200R1.
The CD200–CD200R1 axis is an immunological checkpoint that plays a
pivotal role in maintenance of immune tolerance. CD200R1 is an
inhibitory receptor expressed on T cells and myeloid cells while
CD200, the ligand for CD200R1, is highly expressed on certain
tumors. Binding of tumor associated CD200 to CD200R1 leads to
immune suppression and decreased immune cell killing of cancer
cells. Preclinical data indicate that this mechanism has the
potential to restore the ability for both T-cells and myeloid cells
to kill cancer cells.
The Phase 1 study is an open-label study to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, and preliminary
clinical activity of 23ME-00610 in patients with advanced solid
malignancies who have progressed on all available standard
therapies. Clinical trials registry (clinicaltrials.gov):
NCT05199272.
Reference, drug targets based on human genetics: Nelson et al.,
2015 (Nature Genetics), King et al., 2019 (PLOS Genetics)
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit www.23andMe.com.
Forward looking statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including, without limitation, statements regarding the
future performance of 23andMe’s businesses in consumer genetics and
therapeutics and the growth and potential of its proprietary
research platform. All statements, other than statements of
historical fact, included or incorporated in this press release,
including statements regarding 23andMe’s strategy, financial
position, funding for continued operations, cash reserves,
projected costs, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," “predicts,”
"continue," "will," “schedule,” and "would" or, in each case, their
negative or other variations or comparable terminology, are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on 23andMe’s
current expectations and projections about future events and
various assumptions. 23andMe cannot guarantee that it will actually
achieve the plans, intentions, or expectations disclosed in its
forward-looking statements and you should not place undue reliance
on 23andMe’s forward-looking statements. These forward-looking
statements involve a number of risks, uncertainties (many of which
are beyond the control of 23andMe), or other assumptions that may
cause actual results or performance to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, as filed with the
Securities and Exchange Commission, and as revised and updated by
our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts:Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Apr 2024 to May 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From May 2023 to May 2024